Sign in
SuspendedPhase 3

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial

Key facts

Who runs it
NYU Langone Health
Where
New York, United StatesSee the siteAlso in 5 other countries, 5 sites
Trial code
Status
Suspended
Phase
Phase 3
People taking part
1,200 people, planned
Starts
Dec 2026
Expected to end
Dec 2032
Type of study
Interventional, 3 groups
Treatments tested
  • Guideline-directed medical therapy (GDMT)
  • Coronary artery bypass grafting (CABG)
  • Percutaneous coronary intervention (PCI).
Record updated
5 June 2026
Why it stopped
Study temporarily paused.

Who can take part

Age
55 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Left ventricular ejection fraction (LVEF) ≤ 40% within prior 6 months (any local measurement, made within the past 6 months using echocardiography, multigated acquisition (MUGA), computed tomography (CT) scanning, magnetic resonance imaging (MRI), or ventricular angiography is acceptable, provided no subsequent measurement above 40%)
  • Participants with multivessel CAD (defined as severe 3 vessel disease or 2 vessel disease including left anterior descending (LAD) artery disease) on coronary CT angiography (CCTA) or invasive coronary angiography
  • CAD amenable to either PCI or CABG as determined by the local heart team
  • Participant is willing to comply with all aspects of the protocol, including adherence to the assigned strategy, medical therapy and follow-up visits
  • Participant is able and willing to give written informed consent

Who cannot take part

  • Decompensated heart failure or cardiogenic shock in the past 48 hours prior to randomization
  • Concomitant significant valvular heart disease requiring surgery
  • Prior cardiac surgery
  • Dementia with loss of capacity to consent (clinically evident or previously diagnosed)
  • Stroke within the previous 6 months or spontaneous intracranial hemorrhage at any time
  • History of noncompliance with medical therapy
  • Life expectancy less than the duration of the trial due to non-cardiovascular comorbidity
  • Pregnancy (known to be pregnant; to be confirmed before randomization, if applicable)

Where in United States

Also in 5 other countries, 5 sites

  • NYU Langone HealthNew York, United States

About the trial

What the trial wants to find out

The ISCHEMIA-HF trial will randomize participants with multivessel coronary artery disease (CAD) with ejection fraction (EF) ≤40% in a 1:2:2 fashion to guideline-directed medical therapy (GDMT):coronary artery bypass grafting (CABG):percutaneous coronary intervention (PCI).

The 3 groups in the trial

  • GDMTTreatment being tested

    Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive GDMT.

    Treatment: Guideline-directed medical therapy (GDMT)

  • CABGTreatment being tested

    Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive CABG.

    Treatment: Coronary artery bypass grafting (CABG)

  • PCITreatment being tested

    Participants with multivessel coronary artery disease (CAD) and heart failure with reduced ejection fraction (HFrEF) who are assigned to receive PCI.

    Treatment: Percutaneous coronary intervention (PCI).

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
ISCHEMIA-LVD: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
Record updated
5 June 2026